Show notes
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline, the country is nothing more than a red herring. In this week’s episode of "The Top Line," Fierce Biotech’s Darren Incorvaia chats with Gline about China, artificial intelligence and the exciting year ahead for Roivant’s lead asset brepocitinib.
Highlighted moments
certain kinds of drug discovery, especially certain kinds of antibody discovery, have just become commodity goods. If you want an antibody against a target like TL1A, you can get one.
“I am very worried about the like the long term ramifications of NIH cuts and sort of the the way that academia has been impacted recently”
Transcript
Transcript not available for this episode yet.
More from The Top Line
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
Aug 7, 202620 min
The next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)
Aug 6, 202626 min
Inside Noble’s connected approach to patient support (Sponsored)
Aug 3, 202615 min
Psychedelics, peptides and GLP-1s
Jul 31, 202625 min
GSK’s first lung cancer approval, a new IPO path and more
Jul 24, 202611 min